
Vizle

https://vizle.offnote.co

Contact us: **vizle@offnote.co**

This document was generated automatically by **Vizle**

Your **Personal Video Reader Assistant**

Learn from Videos **Faster** and **Smarter**

VIZLE **PRO / BIZ**

PDF, PPT ~~Watermarks~~

- Convert *entire* videos
- *Customize* to retain all essential content
- Include Spoken *Transcripts*
- Customer support

Visit **https://vizle.offnote.co/pricing** to learn more

VIZLE **FREE PLAN**

PDF only Watermarks

- Convert videos *partially*
- Slides may be *skipped**
- Usage restrictions
- No Customer support

Visit **https://vizle.offnote.co** to try free

Login to Vizle to unlock more slides*


Not for lack of trying!
Neuro-Oncology
Vizle


Crossover Design
Vizle


Results: New GBM
mOS: 19.3 mos from randomization (22.4 mos from surgery)
vs. 15.5 mos from randomization in controls
mMGMT mOS: 26.2 mos from randomization (31 mos from surgery)
vs 21.3 mos from randomization in controls
Survival 1a/c: 13% vs 5.7% at 5 years
Survival advantage also in groups traditionally considered with
poorer prognosis especially older patients
Vizle


Overall Survival in Recurrent GBM
Vizle

https://vizle.offnote.co

Contact us: **vizle@offnote.co**

This document was generated automatically by **Vizle**

Your **Personal Video Reader Assistant**

Learn from Videos **Faster** and **Smarter**

VIZLE **PRO / BIZ**

PDF, PPT ~~Watermarks~~

- Convert *entire* videos
- *Customize* to retain all essential content
- Include Spoken *Transcripts*
- Customer support

Visit **https://vizle.offnote.co/pricing** to learn more

VIZLE **FREE PLAN**

PDF only Watermarks

- Convert videos *partially*
- Slides may be *skipped**
- Usage restrictions
- No Customer support

Visit **https://vizle.offnote.co** to try free

Login to Vizle to unlock more slides*